CN Patent

CN106834291A — 抑制运甲状腺素蛋白表达的组合物和方法

Assigned to Alnylam Pharmaceuticals Inc · Expires 2017-06-13 · 9y expired

What this patent protects

本发明涉及靶向运甲状腺素蛋白(TTR)基因的双链核糖核酸(dsRNA)，以及用所述dsRNA抑制TTR表达的方法。

USPTO Abstract

本发明涉及靶向运甲状腺素蛋白(TTR)基因的双链核糖核酸(dsRNA)，以及用所述dsRNA抑制TTR表达的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN106834291A
Jurisdiction
CN
Classification
—
Expires
2017-06-13
Drug substance claim
No
Drug product claim
No
Assignee
Alnylam Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.